1. Home
  2. CYTK vs CUZ Comparison

CYTK vs CUZ Comparison

Compare CYTK & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • CUZ
  • Stock Information
  • Founded
  • CYTK 1997
  • CUZ 1958
  • Country
  • CYTK United States
  • CUZ United States
  • Employees
  • CYTK N/A
  • CUZ N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • CUZ Real Estate Investment Trusts
  • Sector
  • CYTK Health Care
  • CUZ Real Estate
  • Exchange
  • CYTK Nasdaq
  • CUZ Nasdaq
  • Market Cap
  • CYTK 5.6B
  • CUZ 4.9B
  • IPO Year
  • CYTK 2004
  • CUZ N/A
  • Fundamental
  • Price
  • CYTK $39.48
  • CUZ $26.87
  • Analyst Decision
  • CYTK Strong Buy
  • CUZ Buy
  • Analyst Count
  • CYTK 17
  • CUZ 9
  • Target Price
  • CYTK $81.63
  • CUZ $32.56
  • AVG Volume (30 Days)
  • CYTK 2.6M
  • CUZ 1.5M
  • Earning Date
  • CYTK 05-07-2025
  • CUZ 05-01-2025
  • Dividend Yield
  • CYTK N/A
  • CUZ 4.78%
  • EPS Growth
  • CYTK N/A
  • CUZ N/A
  • EPS
  • CYTK N/A
  • CUZ 0.30
  • Revenue
  • CYTK $18,474,000.00
  • CUZ $853,962,000.00
  • Revenue This Year
  • CYTK $55.84
  • CUZ $11.57
  • Revenue Next Year
  • CYTK $659.85
  • CUZ $4.18
  • P/E Ratio
  • CYTK N/A
  • CUZ $89.79
  • Revenue Growth
  • CYTK 145.34
  • CUZ 6.06
  • 52 Week Low
  • CYTK $32.74
  • CUZ $21.58
  • 52 Week High
  • CYTK $68.76
  • CUZ $32.55
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 46.41
  • CUZ 42.52
  • Support Level
  • CYTK $37.79
  • CUZ $24.93
  • Resistance Level
  • CYTK $40.22
  • CUZ $27.04
  • Average True Range (ATR)
  • CYTK 3.16
  • CUZ 1.22
  • MACD
  • CYTK 0.25
  • CUZ -0.02
  • Stochastic Oscillator
  • CYTK 61.55
  • CUZ 49.12

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

Share on Social Networks: